Immunovia publ AB - Asset Resilience Ratio
Immunovia publ AB (IMMNOV) has an Asset Resilience Ratio of 83.99% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2022)
This chart shows how Immunovia publ AB's Asset Resilience Ratio has changed over time. Check Immunovia publ AB strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Immunovia publ AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see IMMNOV market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr29.27 Million | 83.99% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr29.27 Million | 83.99% |
Asset Resilience Insights
- Very High Liquidity: Immunovia publ AB maintains exceptional liquid asset reserves at 83.99% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Immunovia publ AB Industry Peers by Asset Resilience Ratio
Compare Immunovia publ AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882 |
Diagnostics & Research | 0.14% |
|
Shanghai Labway Clinical Laboratory Co Ltd
SHE:301060 |
Diagnostics & Research | 2.10% |
|
Ningbo MedicalSystem Biotechnology Co Ltd
SHE:300439 |
Diagnostics & Research | 7.27% |
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
|
Green Cross Lab Cell Corporation
KQ:144510 |
Diagnostics & Research | 0.18% |
|
Check Cap Ltd
NASDAQ:CHEK |
Diagnostics & Research | 70.29% |
|
BGI Genomics Co Ltd
SHE:300676 |
Diagnostics & Research | 3.62% |
Annual Asset Resilience Ratio for Immunovia publ AB (2016–2022)
The table below shows the annual Asset Resilience Ratio data for Immunovia publ AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 35.28% | Skr106.04 Million ≈ $11.41 Million |
Skr300.59 Million ≈ $32.35 Million |
-41.46pp |
| 2017-12-31 | 76.73% | Skr192.43 Million ≈ $20.71 Million |
Skr250.77 Million ≈ $26.99 Million |
-14.69pp |
| 2016-12-31 | 91.42% | Skr259.09 Million ≈ $27.88 Million |
Skr283.41 Million ≈ $30.50 Million |
-- |
About Immunovia publ AB
Immunovia AB (publ), a diagnostic company, develops and validates blood test for detecting pancreatic cancer in Sweden. It also focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.